Table 2.

Effect of sulfisoxazole on the pharmacokinetics of furosemide in seven patients with nephrotic syndromea

GroupSubjectMean ± SD
1234567
at½, half-life; Vd, volume of distribution; CL, clearance; AUC, area under the serum concentration versus time curve.
bP < 0.05, significantly different from furosemide alone.
Furosemide alone
t½ (h)1.41.01.51.20.60.91.11.1 ± 0.3
Vd (L)7.010.911.05.16.19.46.38.0 ± 2.4
CL (L/h)3.67.45.12.96.87.04.05.2 ± 1.8
AUC (μg/L per h)33.616.223.641.817.817.330.425.8 ± 9.8
furosemide excretion (mg)33.554.030.959.957.273.532.348.8 ± 15.2
Furosemide + sulfisoxazole
t½ (h)0.90.81.01.10.70.91.10.9 ± 0.1
Vd (L)8.411.817.07.611.613.07.911.0 ± 3.4b
CL (L/h)6.410.911.44.710.99.85.28.5 ± 2.9b
AUC (μg/L per h)18.811.010.625.411.012.223.216.0 ± 6.4b
furosemide excretion (mg)46.147.240.057.754.276.035.954.0 ± 12.3